Evidence map›Paper›PMID 31250167›Full record

ArticleEuropean radiology2019

Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis.

Nihal Martis, Philippe Viau, Thierry Zenone, Fanny Andry, Aurélie Grados, Mikael Ebbo, Emeline Castela, Benoit Brihaye, Eric Denis, Stéphane Liguori and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. [Diagnostics (Basel, Switzerland) · 2023
    Article
  4. Review
  5. MRI and muscle imaging for idiopathic inflammatory myopathies.Brain pathology (Zurich, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Nihal MartisService de Médecine Interne, CHU de Nice, Université Côte d'Azur, Faculté de Médecine de Nice, Nice, France. martis.n@chu-nice.fr.ORCID http://orcid.org/0000-0002-8932-3169
Philippe ViauService de Médecine Nucléaire, CHU de Nice, Université Côte d'Azur, Faculté de Médecine de Nice, Nice, France.
Thierry ZenoneService de Médecine Interne, CH de Valence, Valence, France.
Fanny AndryService de Médecine Interne, CHU Michallon, Grenoble, France.
Aurélie GradosService de Médecine Interne, Hôpital La Timone, AP-HM, Marseille, France.
Mikael EbboService de Médecine Interne, Hôpital La Timone, AP-HM, Marseille, France.
Emeline CastelaService de Médecine Interne, CHU de Nice, Université Côte d'Azur, Faculté de Médecine de Nice, Nice, France.
Benoit BrihayeService de Médecine Interne, CH Saint-Quentin, Saint-Quentin, France.
Eric DenisService de Médecine Interne, CH d'Antibes-Juan-les-Pins, Antibes, France.
Stéphane LiguoriService de Biologie Médicale, CH d'Antibes-Juan-les-Pins, Antibes, France.
Alexandra AudemardService de Médecine Interne, CHU de Caen, Caen, France.
Yoland SchoindreService de Médecine Interne, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.
Anne-Sophie MorinService de Médecine Interne, Hôpital Jean Verdier, AP-HP, Bondy, France.
Benjamin TerrierService de Médecine Interne, Hôpital Cochin, AP-HP, Paris, France.
Laurent MarcqService de Médecine Interne, CH d'Antibes-Juan-les-Pins, Antibes, France.
Nicolas MounierService d'Onco-Hématologie, CHU de Nice, Université Côte d'Azur, Faculté de Médecine de Nice, Nice, France.
Olivier LidoveService de Médecine Interne, CH Croix St-Simon, Paris, France.
Jean-Philippe ChaborelService de Médecine Nucléaire, Institut Tzanck Mougins, Mougins, France.
Denis QuinsatService de Médecine Interne, CH d'Antibes-Juan-les-Pins, Antibes, France.
Centre Procédés, Energies Renouvelables et Systèmes Energétiques · FRUniversité Côte d'Azur · FRHôpital de la Timone · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier de Saint-Quentin · FRCentre Hospitalier de Valence · FRCentre Hospitalier Universitaire de Caen Normandie · FRCentre Hospitalier Universitaire de Grenoble · FRGroupe Hospitalier Diaconesses Croix Saint-Simon · FRHôpital Cochin · FRInstitut Arnault Tzanck · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study a muscle-to-muscle standardised uptake value (SUV) ratio with FDG-PET/CT (FDG-PET) as a marker for the detection of disease activity in dermatomyositis (DM).

methodsPatients with DM (n = 24) who met the European Neuro-Muscular Centre diagnostic criteria were retrospectively identified over a 3-year period through a national survey. Muscle biopsy was performed in all patients. Maximum SUV was measured in proximal muscles (SUV

resultsDM patients presented with proximal and symmetrical muscle uptake. Differences in SUV

conclusionA muscle-to-muscle SUV KEY POINTS: • [18F]-FDG PET-scanner standardised uptake value (SUV) could reflect disease activity in dermatomyositis (DM). • A ratio of SUV in proximal muscles (SUV

Indexed as

AdultAgedAged, 80 and overDermatomyositisFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMuscle, SkeletalPositron Emission Tomography Computed TomographyRadiopharmaceuticalsReproducibility of ResultsRetrospective StudiesSensitivity and SpecificityFluorodeoxyglucose F18RadiopharmaceuticalsAmyopathic dermatomyositisDermatomyositisFluorodeoxyglucose F18MyositisPositron-emission tomography

Identifiers

PMID31250167
OpenAlexW2955737711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.